Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies

Richard R. Rubin, Mark Peyrot

    Research output: Contribution to journalArticlepeer-review

    Fingerprint Dive into the research topics of 'Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies'. Together they form a unique fingerprint.